TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03072043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
Study: NCT01731847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the combination group
Description: Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
Study: NCT00610844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary radiofrequency ablation
Description: CT-guided pulmonary radiofrequency ablation
Study: NCT03506139

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
Study: NCT02779777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral tablet
Study: NCT01943786

Intervention type: DRUG
Intervention: FOLFIRI + Cetuximab
Description: Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
Study: NCT01090102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine (5-aminosalicylic acid, Apriso)
Description: Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Study: NCT03859193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Video
Description: A 10 - 15 minute video
Study: NCT00510289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice a day until progression or unacceptable toxicity develops.
Study: NCT03030820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Cleaning
Description: This is standard of care dental cleaning as is guided by the initial dental evaluation
Study: NCT04062656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relatlimab
Description: relatlimab (80mg flat dose) administered IV over 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m² IV over 1 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m² IV over 1 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m² IV over 1 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m² IV over 1 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluorouracil 2600mg/m² IV over 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluorouracil 2600mg/m² IV over 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid (FA)
Description: Folic acid 200mg/m² IV over 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid (FA)
Description: Folic acid 200mg/m² IV over 30 min
Study: NCT03237416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 (darolutamide)
Description: In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
Study: NCT00658658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab administered by intravenous infusion
Study: NCT02328235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Saturated Fat Diet
Description: Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study.
Study: NCT03134118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
Study: NCT02658825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 2400 milligram (mg)
Description: Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 3000 mg
Description: Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
Study: NCT01997697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior change program
Description: behavior change program among patients with obesity
Study: NCT02283957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02658825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 2400 mg)
Description: Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 3000 mg)
Description: Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
Study: NCT02745340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetate by Citrate substitution and vice versa
Description: substitution of acetate by citrate in dialysis fluid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetate by Citrate substitution and vice versa
Description: substitution of acetate by citrate in dialysis fluid
Study: NCT01094184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
Study: NCT02658825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
Study: NCT04366427

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L-HBO
Description: as previously described.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HBO
Description: as previously described.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 30% O2
Description: as previously described
Study: NCT02154165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The infants were randomized to phototherapy with either blue og turquoise light
Study: NCT01283867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study: NCT02342353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT03941418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boulardii
Description: Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered with placebo of same appearance, colour and taste once daily.
Study: NCT01698203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
Description: The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
Study: NCT01283867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study: NCT04342429

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton-beam Therapy for Small Cell Lung Cancer
Description: The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
Study: NCT04397926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized neoantigen peptides vaccine
Description: Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
Study: NCT02613702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Original Free Gingival Graft technique
Description: Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Free Gingival Graft technique
Description: Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
Study: NCT04329000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: On-demand Esomeprazole 40 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Continuous Esomeprazole 40 mg QD
Study: NCT01945268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inactivated trivalent influenza vaccine
Description: 0.5 ml dose injected intramuscularly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 ml dose injected intramuscularly
Study: NCT05982145

Intervention type: OTHER
Intervention: Individual interviews
Description: Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems

Intervention type: OTHER
Intervention: Individual interviews
Description: Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems

Intervention type: OTHER
Intervention: Focus groups
Description: Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday

Intervention type: OTHER
Intervention: Questionary and measures
Description: To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
Study: NCT01698203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
Description: The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
Study: NCT03635632

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CART cells
Description: Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CART cells
Description: Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI.
Study: NCT04902430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power chain and Crimpable hook for En-Masse Retraction
Description: Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T- Loop
Description: Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
Study: NCT04916392

Intervention type: DRUG
Intervention: Liposomal bupivacaine
Description: 5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
Study: NCT05723744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias
Description: For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline
Study: NCT01417221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study: NCT03073863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Analysis
Study: NCT02648594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hook wire CT guided
Description: The intervention consist to place a CT-guided hook wire in lung patient
Study: NCT00093262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study: NCT04366427

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 50% O2
Description: as previously described
Study: NCT00578669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20mg once daily for 16 weeks
Study: NCT00093262

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02673138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin
Description: basal interruption with canagliflozin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: basal interruption without canagliflozin
Description: basal interruption
Study: NCT04406376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Treatment of Bell's Palsy with prednisone, with or without tapering down.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Treatment of Bell's Palsy with prednisone, with or without tapering down.